Reaction
Bacterial Vaginosis reporting signals
As of the last recalculation, Bacterial Vaginosis appears in 1,530 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is COPPER (PRR 101.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Copper | 266 | 101.4 | 102.0 |
| Etonogestrel And Ethinyl Estradiol | 52 | 33.0 | 33.1 |
| Metronidazole | 89 | 20.1 | 20.1 |
| Levonorgestrel | 223 | 17.5 | 17.5 |
| Infliximab-Dyyb | 34 | 16.2 | 16.2 |
| Metronidazole Topical | 50 | 14.7 | 14.7 |
| Ocrelizumab | 52 | 11.8 | 11.8 |
| Miconazole Nitrate | 7 | 11.0 | 11.0 |
| Estradiol | 59 | 9.6 | 9.6 |
| Desoximetasone | 13 | 9.4 | 9.4 |
| Etonogestrel | 27 | 7.8 | 7.8 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate | 20 | 7.8 | 7.8 |
| Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate | 21 | 7.0 | 7.0 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 4 | 6.3 | 6.3 |
| Ozanimod Hydrochloride | 3 | 4.9 | 4.9 |
| Ofatumumab | 10 | 4.1 | 4.1 |
| Bimekizumab | 4 | 2.6 | 2.6 |